Infliximab for the treatment of pyoderma gangrenosum: a randomised, double blind, placebo controlled trial

T N Brooklyn; M G S Dunnill; A Shetty; J J Bowden; J D L Williams; C E M Griffiths; A Forbes; R Greenwood; C S Probert

doi:10.1136/gut.2005.074815

Infliximab for the treatment of pyoderma gangrenosum: a randomised, double blind, placebo controlled trial

T N Brooklyn, M G S Dunnill, A Shetty, J J Bowden, J D L Williams, C E M Griffiths, A Forbes, R Greenwood, C S Probert

Research output: Contribution to journal › Article › peer-review

531 Citations (Scopus)

Abstract

Pyoderma gangrenosum (PG) is a chronic ulcerating skin condition that often occurs in association with inflammatory bowel disease. There have been a number of reports of PG responding to infliximab, a monoclonal antibody against tumour necrosis factor alpha.

Original language	English
Pages (from-to)	505-509
Number of pages	5
Journal	Gut
Volume	55
Issue number	4
DOIs	https://doi.org/10.1136/gut.2005.074815
Publication status	Published - Apr 2006

Keywords

Adult
Aged
Aged, 80 and over
Antibodies, Monoclonal
Dermatologic Agents
Double-Blind Method
Female
Humans
Inflammatory Bowel Diseases
Male
Middle Aged
Pyoderma Gangrenosum
Quality of Life
Treatment Outcome

Access to Document

10.1136/gut.2005.074815

Cite this

@article{7a19e7464d2c4744b11544a76072c2f0,

title = "Infliximab for the treatment of pyoderma gangrenosum: a randomised, double blind, placebo controlled trial",

abstract = "Pyoderma gangrenosum (PG) is a chronic ulcerating skin condition that often occurs in association with inflammatory bowel disease. There have been a number of reports of PG responding to infliximab, a monoclonal antibody against tumour necrosis factor alpha.",

keywords = "Adult, Aged, Aged, 80 and over, Antibodies, Monoclonal, Dermatologic Agents, Double-Blind Method, Female, Humans, Inflammatory Bowel Diseases, Male, Middle Aged, Pyoderma Gangrenosum, Quality of Life, Treatment Outcome",

author = "Brooklyn, {T N} and Dunnill, {M G S} and A Shetty and Bowden, {J J} and Williams, {J D L} and Griffiths, {C E M} and A Forbes and R Greenwood and Probert, {C S}",

year = "2006",

month = apr,

doi = "10.1136/gut.2005.074815",

language = "English",

volume = "55",

pages = "505--509",

journal = "Gut",

issn = "0017-5749",

publisher = "BMJ Publishing Group",

number = "4",

}

TY - JOUR

T1 - Infliximab for the treatment of pyoderma gangrenosum: a randomised, double blind, placebo controlled trial

AU - Brooklyn, T N

AU - Dunnill, M G S

AU - Shetty, A

AU - Bowden, J J

AU - Williams, J D L

AU - Griffiths, C E M

AU - Forbes, A

AU - Greenwood, R

AU - Probert, C S

PY - 2006/4

Y1 - 2006/4

N2 - Pyoderma gangrenosum (PG) is a chronic ulcerating skin condition that often occurs in association with inflammatory bowel disease. There have been a number of reports of PG responding to infliximab, a monoclonal antibody against tumour necrosis factor alpha.

AB - Pyoderma gangrenosum (PG) is a chronic ulcerating skin condition that often occurs in association with inflammatory bowel disease. There have been a number of reports of PG responding to infliximab, a monoclonal antibody against tumour necrosis factor alpha.

KW - Adult

KW - Aged

KW - Aged, 80 and over

KW - Antibodies, Monoclonal

KW - Dermatologic Agents

KW - Double-Blind Method

KW - Female

KW - Humans

KW - Inflammatory Bowel Diseases

KW - Male

KW - Middle Aged

KW - Pyoderma Gangrenosum

KW - Quality of Life

KW - Treatment Outcome

U2 - 10.1136/gut.2005.074815

DO - 10.1136/gut.2005.074815

M3 - Article

C2 - 16188920

SN - 0017-5749

VL - 55

SP - 505

EP - 509

JO - Gut

JF - Gut

IS - 4

ER -